Prognostic and predictive markers in medullary thyroid carcinoma

Endocrine Pathology

Volumn 23, Issue 4, 2012, Pages 232-242

  Erovic, Boban M ^a   Kim, Dae ^a   Cassol, Clarissa ^a   Goldstein, David P ^a   Irish, Jonathan C ^a   Asa, Sylvia L ^a   Mete, Ozgur ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Angioinvasion; Medullary thyroid carcinoma; Peptide receptor radionuclide therapy; Personalized medicine; Target proteins; Targeted anticancer therapy

Indexed keywords

BETA CATENIN; BMI1 PROTEIN; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CD9 ANTIGEN; CHROMOGRANIN A; CYCLIN D1; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKERATIN 7; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTATHIONE TRANSFERASE; INTERSTITIAL COLLAGENASE; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN WISP 1; PROTEIN WISP 2; SONIC HEDGEHOG PROTEIN; STRATIFIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR GLI3; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; AKT SIGNALING PATHWAY; ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CELL ADHESION; CELL CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RECURRENT DISEASE; SHH SIGNALING PATHWAY; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA; TISSUE MICROARRAY; WNT SIGNALING PATHWAY;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CANADA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; SURVIVAL RATE; THYROID GLAND; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84872178781     PISSN: 10463976     EISSN: 15590097     Source Type: Journal    
DOI: 10.1007/s12022-012-9225-8     Document Type: Article

References (53)

1. DeLellis RA, Lloyd RV, Heitz PU, editors. World Health Organization Classification of Tumours. Pathology and genetics of tumours of endocrine organs. IARC Press: Lyon, 2004.
2. Mete O, Asa SL. Composite medullary and papillary thyroid carcinoma in a patient with MEN 2B: Case report and review of c-cell lesions of the thyroid. Pathol Case Rev 14:208-13, 2009.
3. Ameur N, Lacroix L, Roucan S, et al. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways. Endocr Relat Cancer 16:1261-72, 2009.
4. Moley JF, Fialkowski EA Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 31:946-56, 2007. (Pubitemid 46716779)
5. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107:2134-42, 2006. (Pubitemid 44665646)
6. Cupisti K, Wolf A, Raffel A, et al. Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution's experience over 20 years. Ann Surg 246:815-21, 2007. (Pubitemid 350035658)
7. Faik Erdogan M, Gursoy A, Erdogan G, Kamel N. Radioactive iodine treatment in medullary thyroid carcinoma. Nucl Med Commun 27:359-62, 2006. (Pubitemid 44315045)
8. Fialkowski EA, Moley JF. Current approaches to medullary thyroid carcinoma, sporadic and familial. J Surg Oncol 94:737-47, 2006. (Pubitemid 44902074)
9. van Veelen W, de Groot JW, Acton DS, et al. Medullary thyroid carcinoma and biomarkers: past, present and future. J Intern Med 266:126-40, 2009.
10. Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 4:22-32, 2008. (Pubitemid 350291115)
11. Ball DW. Medullary thyroid cancer: therapeutic targets and molecular markers. Curr Opin Oncol 19:18-23, 2007. (Pubitemid 44885595)
12. Carlomagno F, Santoro M. Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. J Chemother 16:49-51, 2004. (Pubitemid 40065281)
13. Kodama Y, Asai N, Kawai K, et al. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci 96:143-8, 2005. (Pubitemid 40575914)
14. Putzer BM, Drosten M. The RET proto-oncogene: a potential target for molecular cancer therapy. Trends Mol Med 10:351-7, 2004. (Pubitemid 38881525)
15. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of Sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-9, 2008.
16. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708-13, 2008.
17. Wells S, You YN, Lakhani V, et al. A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. J Clin Oncol (Meeting Abstracts) 24:5553, 2006.
18. Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23:6056-63, 2004. (Pubitemid 39178858)
19. Plaza-Menacho I, Mologni L, Sala E, et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 282:29230- 40, 2007. (Pubitemid 350043334)
20. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98:326-34, 2006. (Pubitemid 43338212)
21. Juweid M, Sharkey RM, Behr T, et al. Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies. J Nucl Med 37:905-11, 1996. (Pubitemid 126447119)
22. Juweid M, Sharkey RM, Behr T, et al. Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res 55:5946s-51s, 1995.
23. Juweid ME, Hajjar G, Swayne LC, et al. Phase I/II trial of (131)IMN- 14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer 85:1828-42, 1999.
24. Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 24:1705-11, 2006. (Pubitemid 46622142)
25. Mete O, Asa SL. Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod Pathol 24:1545-52, 2011.
26. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794-801, 2009.
27. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29:2660-66, 2011.
28. Bass MB, Sherman SI, Schlumberger MJ, Davis MT, Kivman L, et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 95:5018-27, 2010.
29. Sharafinski ME, Ferris RL, Ferrone S, Grandis Jr. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 32:1412-21, 2010.
30. Quidville V, Segond N, Tebbi A, et al. Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice. Thyroid 19:613-21, 2009.
31. Goto M, Mitra RS, Liu M, et al. Rap1 stabilizes beta-catenin and enhances beta-catenin-dependent transcription and invasion in squamous cell carcinoma of the head and neck. Clin Cancer Res 16:65-76, 2010.
32. Asa SL. Pancreatic endocrine tumors. Mod Pathol Suppl 2: S66- 77, 2011.
33. Zhu CQ, Shih W, Ling CH, Tsao MS. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 59:790-800, 2006. (Pubitemid 44211740)
34. Masuko Katoh, M Katoh. WNT Signaling Pathway and stem cell signaling network. Clin Cancer Res 13:4042-5, 2007.
35. Weinberger PM, Adam BL, Gourin CG, et al. Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/ Wnt-pathway activation in thyroid carcinoma. Arch Otolaryngol Head Neck Surg 133:503-10, 2007. (Pubitemid 46799789)
36. Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 9:501-7, 2009.
37. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15:1126- 32, 2009.
38. Mitsiades CS, Hayden P, Kotoula V, et al. Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition. J Clin Endocrinol Metab 92:4845-52, 2007. (Pubitemid 350223468)
39. Paik PK, Rudin CM, Brown A, et al. A phase I study of obatoclaxmesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol 66:1079-85, 2010.
40. Thévenin AF, Zony CL, Bahnson BJ, Colman RF. GST pi modulates JNK activity through a direct interaction with JNK substrate, ATF2. Protein Sci 20:834-48, 2011.
41. Edelman MJ. Novel cytotoxic agents for non-small cell lung cancer. J Thorac Oncol 1:752-5, 2006. (Pubitemid 47163974)
42. Brunner M, Thurnher D, Pammer J, et al. Expression of hedgehog signaling molecules in Merkel cell carcinoma. Head Neck 32:333- 40, 2009.
43. Peukert S, Miller-Moslin K. Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics. Chem Med Chem 5:500-12, 2010.
44. Sánchez-Beato M, Sánchez E, González-Carreró J, et al. Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays. Mod Pathol :684-94, 2006.
45. Vormittag L, Thurnher D, Geleff S, et al. Co-expression of Bmi-1 and podoplanin predicts overall survival in patients with squamous cell carcinoma of the head and neck treated with radio(chemo)- therapy. Int J Radiat Oncol Biol Phys 1;73:913-8, 2009.
46. Reinisch CM, Uthman A, Erovic BM, Pammer J. Expression of BMI-1 in normal skin and inflammatory and neoplastic skin lesions. J Cutan Pathol 34:174-80, 2007. (Pubitemid 46145558)
47. Venkataraman S, Alimova I, Fan R, Harris P, Foreman N, Vibhakar R. MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence. PLoS One 5:e10748, 2010.
48. Yu Q, Su B, Liu D, et al. Antisense RNA-mediated suppression of Bmi-1 gene expression inhibits the proliferation of lung cancer cell line A549. Oligonucleotides 17:327-35, 2007. (Pubitemid 47463364)
49. Godlewski J, Nowicki MO, Bronisz A, et al. Targeting of the Bmi-1 oncogene/stemcell renewal factor bymicroRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 68:9125-30, 2008.
50. Mendelsohn G, Wells SA Jr, Baylin SB. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease. Cancer 54:657-62, 1984. (Pubitemid 14060346)
51. Ezzat S, Huang P, Dackiw A, Asa SL. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res 11:1336-41, 2005. (Pubitemid 40175788)
52. Gulenchyn KY, Yao X, Asa SL, Singh S, Law C 2012 Radionuclide therapy in neuroendocrine tumours: a systematic review. Clin Oncol (R Coll Radiol);24(4):294-308, 2012.
53. Iten F, Müller B, Schindler C, et al. Response to [90Yttrium- DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res 13:6696-702, 2007. (Pubitemid 350206806)